Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of “Buy” by Analysts
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has received a consensus recommendation of “Buy” from the ...
Nature3y
Arcturus—a clinical-stage mRNA therapeutics and vaccines company
Neda Safarzadeh, Sr. Director, Head of IR, PR & Marketing, Arcturus Therapeutics Holdings Inc., San Diego, CA, USA, Tel: +1-858-900-2682 Arcturus Therapeutics, based ...
Business Insider15d
Arcturus Therapeutics price target lowered to $60 from $63 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $60 from $63 and keeps a Buy rating on the shares. Arcturus on Thursday announced that interim ...
Benzinga.com15d
Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock
Analysts' ratings for Arcturus Therapeutics ARCT over the last quarter vary from bullish to bearish, as provided by 8 analysts. The table below offers a condensed view of their recent ratings ...
ETF Daily News19d
Arcturus Therapeutics (ARCT) Projected to Post Quarterly Earnings on Thursday
HC Wainwright reiterated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Friday, February 14th. BTIG Research initiated coverage on shares ...
Morningstar16d
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and ...
Yahoo Finance15d
Q4 2024 Arcturus Therapeutics Holdings Inc Earnings Call
Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc Padmanabh ...